

SPINRAZA - (EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML) ; Solution)

Generic Name	NUSINERSEN SODIUM	Innovator	Biogen
Dosage	EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML) ; Solution	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	SPINRAZA is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.